Voyager Therapeutics is a gene therapy company focused on developing treatments and platform technologies. Co.'s team has developed a proprietary adeno-associated virus (AAV) capsid discovery platform called TRACER (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) to facilitate the selection of AAV capsids with blood brain barrier crossing and cell-specific transduction properties for particular therapeutic applications. The TRACER discovery platform is a functional RNA-based AAV capsid discovery platform that allows for rapid in vivo evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates. The VYGR average annual return since 2015 is shown above.
The Average Annual Return on the VYGR average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether VYGR average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VYGR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|